| Model Number |
305U227 |
| Medical Device Problem Codes |
Gradient Increase (1270); Device Stenosis (4066)
|
| Health Effect - Clinical Code |
Aortic Valve Stenosis (1717)
|
| Date of Event |
10/30/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
This regulatory report is being submitted due to retrospective review through capa 624392.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Medtronic received information that 4 years and 3 months post implant of this 27mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was reported as moderate aortic stenosis and a gradient of 29.8mmhg.No intervention or adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
B1, b2, b5, h1 and imf (annex f) code updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that an intervention was scheduled.No additional adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b.1: adv evnt/prod prob: b.2: outcome attributed to adverse event b.3: date of event: b.5: event description medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that reported subsequently, 1 year and 10 months later, a second evaluation occurred.An intervention was scheduled.No additional adverse patient effects were reported.Subsequently, 2 days later, the patient successfully had a 26mm transcatheter valve-in-valve replacement.No additional adverse patient effects were reported.
|
| |
|
Search Alerts/Recalls
|